Cognitive research

Cognitive reserve in amyotrophic lateral sclerosis (ALS): a population-based longitudinal study

Emmet Costello,1,2 James Rooney,3,4 Marta Pinto-Grau,1,2 Tom Burke,1,2 Marwa Elamin,2 Peter Bede,2 Roisin McMackin,2 Stefan Dukic,2,5 Alice Vajda,2 Mark Heverin,2 Orla Hardiman,2 Niall Pender1,2

ABSTRACT

Background Amyotrophic lateral sclerosis (ALS) is often associated with cognitive and/or behavioural impairment. Cognitive reserve (CR) may play a protective role in offsetting cognitive impairment. This study examined the relationship between CR and longitudinal change in cognition in an Irish ALS cohort.

Methods Longitudinal neuropsychological assessment was carried out on 189 patients over 16 months using the Edinburgh cognitive and behavioural ALS screen (ECAS) and an additional battery of neuropsychological tests. CR was measured by combining education, occupation and physical activity data. Joint longitudinal and time-to-event models were fitted to investigate the associations between CR, performance at baseline and decline over time while controlling for non-random drop-out.

Results CR was a significant predictor of baseline neuropsychological performance, with high CR patients performing better than those with medium or low CR. Better cognitive performance in high CR individuals was maintained long-termly for ECAS, social cognition, executive functioning and confrontational naming. Patients displayed little cognitive decline over the course of the study, despite controlling for non-random drop-out.

Conclusions These findings suggest that CR plays a role in the presentation of cognitive impairment at diagnosis but is not protective against cognitive decline. However, further research is needed to examine the interaction between CR and other objective correlates of cognitive impairment in ALS.

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the upper and lower motor neurons that results in a relentless paralysis and death.1 Fifteen percent of patients with ALS meet criteria for frontotemporal dementia (FTD), while 30% of non-demented patients will have cognitive impairment.2 These changes have a detrimental effect on patient adherence to treatment, their survival and are associated with greater caregiver burden.3–5

It remains unclear as to the point at which cognitive impairment emerges and the extent to which cognition declines in ALS. Recent studies suggest that cognitive decline coincides with disease stage (using both Kings and MiTo staging systems),6,7 although these data are based on cross-sectional design. Longitudinal studies have largely found that cognitive impairment emerges early in the disease. Those who are impaired at diagnosis subsequently decline over time while those who are unimpaired at diagnosis appear to remain cognitively intact throughout their illness.8–11 These studies are often limited by their high attrition rates, biasing estimates of true decline due to drop-out of those with faster disease progression. Joint longitudinal and time to event models (joint models) have gained popularity for their utility in handling data missing-not-at-random and improving statistical power.12 By applying joint modelling to longitudinal neuropsychological data in ALS, we can get a better estimate of the true rate of cognitive decline. A potential mediator of cognitive change, which may account for some of the varied presentations in ALS, is cognitive reserve (CR). Theories of CR stipulate that neural enrichment, through education, occupation and physical activity increases an individual’s neural resources (eg, greater grey matter volume or white matter tract integrity).13 As the disease spreads across networks, individuals recruit reserve neural resources to deal with cognitive demands, a process known as compensation. Educational attainment, occupational complexity and leisure activity are often used as proxy measures of CR, either in isolation or combined to form a latent construct.

There is indirect evidence that CR plays a protective role in ALS. ALS patients with comorbid FTD are older, have lower educational attainment and poorer survival.14 Executive functioning and verbal memory are protected by CR in a range of other neurodegenerative conditions.15–18

Here, we have examined the relationship between CR and longitudinal neuropsychological performance in ALS. We hypothesise that higher CR is associated with improved cognitive performance at baseline and with a reduced slope of decline over time. We have applied a multiple variable model, using the shared variance of several variables, to create a ‘latent’ measure of CR which can offer a less biased measure than using an individual proxy in isolation.19

METHODS

Participants

One hundred and eighty-nine patients with ALS were recruited for this longitudinal,
population-based research study. Participants were recruited as part of ongoing longitudinal studies of neuropsychological deficits in an Irish ALS cohort from 2012–2019. Participants were assessed within the first year of their diagnosis and reassessed three further times, 4 months apart. Assessments took place in a quiet room in Beaumont Hospital, Dublin, Ireland or in the participants home. Exclusion criteria included: (1) history of an intellectual or learning disability, (2) history of a comorbid neurological, psychiatric or medical condition affecting cognition, (3) alcohol dependence syndrome, (4) if the person was a non-native English speaker or (5) a comorbid diagnosis of FTD. Occupational history, education and physical activity data were derived from Irish EuroMOTOR project data, a study of environmental risk factors of ALS. Clinical data were accessed through the Irish ALS register.

**Materials**

CR score was calculated by combining traditional proxies of CR, namely: education, occupation and physical activity. Education score was the total years an individual spent in full time education. Occupation was coded according to complexity using the International Standard Classification of Occupations-88, inverted so that jobs with increasing complexity had higher scores, and then categorised into nine categories ranging from 1 (elementary occupations) to 9 (legislators, senior officials and managers). Occupation score was the sum of years a person spent in each occupation multiplied by its category. This approach matches how the CR index questionnaire was developed, capturing the time an individual spent in a job as well as the cognitive complexity of that job. Physical activity score was the total number of years a person reported as engaging in each sport/exercise. Each CR subdomain was converted to a z-score using the sample mean and SD and then averaged to give a CR total score.

In the absence of direct biomarkers of the underlying spread of pathological changes, disease progression was approximated using time from disease onset to neuropsychological assessment, as described in previous studies. The Edinburgh cognitive and behavioural ALS screen (ECAS) is a sensitive screening tool of cognition in ALS. It measures three ALS-specific functions, language, verbal fluency and executive functioning, and two ALS non-specific functions, memory and visuospatial functioning. To examine cognition over time, while limiting the influence of practice effects, alternative ECAS versions were used, that is, ECAS A-B-C.

Participants were also administered the FAS verbal fluency test, the Boston Naming Test (BNT), the Reading the Mind in the Eyes Test (RMET), the Colour-Word Interference Task (CWIT), the Logical Memory test from the Wechsler Memory Scale–III and the Rey Auditory Verbal Learning Test (RAVLT). These provided accurate measurements of executive functioning, verbal fluency, language, memory and social cognition. To limit the influence of motor disability, Verbal Fluency Index was calculated on verbal fluency tasks and total errors was used instead of completion time on the CWIT, as described in previous studies. Cognitive performance raw scores were converted to z-scores using test manuals and published age, IQ and gender matched healthy control normative data. A summary of each neuropsychological test, the cognitive domain it measures, and a brief description of the task can be found in [Table 1](#).

**Statistical analysis**

Linear mixed effects models were used to examine the association between CR and neuropsychological performance over the course of 16 months. Linear mixed effects models are a robust means of dealing with missing data, a particularly relevant issue with such a rapidly progressing population with high attrition. We applied additional methods to cater for nonlinear data (see online supplemental material). In these models the intercept and slope were fitted as random effects, allowing them to vary for each individual. Each mixed model included fixed effect terms for time, age, CR score and an interaction between CR and neuropsychological performance. The fixed effect term for CR represents the association between baseline neuropsychological performance and CR. The time by CR interaction term represents the association between baseline neuropsychological performance and time. The fixed effect term for CR represents the association between baseline neuropsychological performance and CR.
Cognition

The association between the slope of change over time and CR. A Cox survival model was constructed with survival as the outcome variable, and known risk factors for shorter survival as predictors, namely age,\(^33\) diagnostic delay,\(^34\) site of onset,\(^35\) and C9orf72 repeat expansion status (see table 2).\(^36\)

The longitudinal mixed model and Cox survival models were then used to create joint longitudinal and time-to-event models (joint models), using the R package JMBayes.\(^37\) This analysis enabled the model to control for non-random drop-out in our longitudinal data, resulting in less biased effect estimates. Joint models also provide a measurement of the association between each cognitive measure and death.\(^38\) Analyses were carried out using R statistical software V3.6.3.\(^39\)

Informed written consent was given by all participants.

**RESULTS**

**Demographic information**

Participant demographic information at each time point is provided in table 2. Participants first assessment occurred on average 19 months after their first symptoms. Attrition rate was 79% over the course of the study, representative of the rapidly progressive nature of the disease.

**Table 2** Demographic characteristics, including age, education, sex, site of onset, time from onset to baseline, familial/sporadic family history and C9orf72 status at each time point

<table>
<thead>
<tr>
<th>Participant characteristics</th>
<th>Time 1 (n=189)</th>
<th>Time 2 (n=117)</th>
<th>Time 3 (n=80)</th>
<th>Time 4 (n=49)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean years (SD)</td>
<td>63.59 (11.42)</td>
<td>61.64 (12.09)</td>
<td>60.52 (12.64)</td>
<td>58.94 (12.57)</td>
</tr>
<tr>
<td>Education, mean years (SD)</td>
<td>13.8 (3.82)</td>
<td>13.97 (3.41)</td>
<td>14.28 (3.36)</td>
<td>13.94 (2.93)</td>
</tr>
<tr>
<td>Sex, n</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>119</td>
<td>77</td>
<td>54</td>
<td>34</td>
</tr>
<tr>
<td>Female</td>
<td>70</td>
<td>40</td>
<td>27</td>
<td>15</td>
</tr>
<tr>
<td>Site of onset, n</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bulbar</td>
<td>44</td>
<td>24</td>
<td>12</td>
<td>4</td>
</tr>
<tr>
<td>Spinal</td>
<td>145</td>
<td>93</td>
<td>69</td>
<td>45</td>
</tr>
<tr>
<td>Time from onset to assessment, mean months (SD)</td>
<td>19.48 (13.29)</td>
<td>25.4 (15.1)</td>
<td>30.11 (14.74)</td>
<td>34.53 (15.52)</td>
</tr>
<tr>
<td>ALSFRS-R, mean (SD)</td>
<td>36.5 (7.6)</td>
<td>33.43 (7.84)</td>
<td>32.34 (8.29)</td>
<td>31.4 (8.63)</td>
</tr>
<tr>
<td>Delta ALSFRS-R, change in ALSFRS-R per month</td>
<td>–</td>
<td>0.52</td>
<td>0.23</td>
<td>0.21</td>
</tr>
<tr>
<td>Familial/sporadic, n</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Familial</td>
<td>31</td>
<td>23</td>
<td>17</td>
<td>13</td>
</tr>
<tr>
<td>Sporadic</td>
<td>158</td>
<td>94</td>
<td>63</td>
<td>36</td>
</tr>
<tr>
<td>C9orf72 status, n</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>15</td>
<td>11</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Negative</td>
<td>174</td>
<td>106</td>
<td>75</td>
<td>45</td>
</tr>
<tr>
<td>El escorial diagnostic status, n</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Definite</td>
<td>92</td>
<td>50</td>
<td>33</td>
<td>23</td>
</tr>
<tr>
<td>Probable</td>
<td>59</td>
<td>44</td>
<td>29</td>
<td>14</td>
</tr>
<tr>
<td>Possible</td>
<td>38</td>
<td>23</td>
<td>18</td>
<td>12</td>
</tr>
<tr>
<td>Strong criteria status, n</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALSn</td>
<td>140</td>
<td>89</td>
<td>67</td>
<td>43</td>
</tr>
<tr>
<td>ALSi</td>
<td>33</td>
<td>19</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>ALSbic</td>
<td>6</td>
<td>2</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>ALSi bic</td>
<td>10</td>
<td>7</td>
<td>3</td>
<td>1</td>
</tr>
</tbody>
</table>

**CR as a predictor of cognition at baseline**

CR score was a significant predictor of baseline performance on the ECAS (including ALS-specific and non-specific subscores), RMET, CWIT (inhibition and switching scores), BNT and logical memory (immediate and delayed recall). Higher CR was positively associated with higher test performance. However, CR was not a significant predictor of baseline verbal fluency or RAVLT (total or delayed) score (see table 3). Full model summaries are provided in online supplemental table 1.

**CR as a predictor of longitudinal cognition**

Longitudinal neuropsychological scores, adjusted for age, site of onset, diagnostic delay and C9orf72 status through joint modeling, are displayed in figure 1.

Individuals were divided into high (CR z-score greater than 1), medium (CR z-score between −1 and 1) and low (CR z-score < −1) CR groups to illustrate the effect of CR over time. For ECAS, RMET, CWIT and BNT, high CR individuals displayed greater performance than medium and low CR groups over time. For logical memory, high medium and low CR regressed towards the mean over time, with high CR groups declining and low CR groups improving.
Survival risk factors
Joint models rely on the construction of Cox survival models to control for non-random drop-out. Controlling for the effects of age, diagnostic delay, site of onset and C9orf72 repeat expansion status, lower ECAS ALS-specific and RAVLT total score were associated with shorter survival. Conversely, higher logical memory immediate score was associated with shorter survival. Table 4 displays the association between each longitudinal outcome and survival after joint modelling using JMBayes, specified with the current value association structure.

DISCUSSION
This study found that CR is associated with baseline differences in neuropsychological performance in a population-based cohort. These differences were most notable for ECAS, social cognition, executive functioning and confrontational naming, where higher performance in high CR individuals was maintained 16 months from baseline. Verbal fluency was not associated with higher CR despite the fact that fluency is often the most sensitive test for cognitive impairment in ALS. These findings may suggest that CR does not protect against fluency deficits, or that the disease has progressed to the stage where it has overcome any protective effect for this function.

For episodic memory (ie, logical memory tasks), high CR individuals performed better at baseline but then declined to a greater extent than low CR groups over time. This may suggest that CR plays a differential role in protecting functions commonly affected by ALS, namely executive functioning, language and social cognition, but is less influential on less implicated functions, such as memory.

ECAS ALS-specific deficits were associated with shorter survival, which is consistent with previous studies, as was RAVLT total score. Higher logical memory immediate score was associated with shorter survival. While executive impairment is a known risk factor for shorter survival in ALS, the role of memory is less established. Similar findings have been observed in Alzheimer’s research, where individuals with higher CR perform better on memory tasks in the early disease stage, but then suffer from a more rapid disease decline. 40

These findings in an ALS cohort are similar to those of other neurodegenerative diseases. In Parkinson’s disease high CR patients perform better on attention, executive functioning and visuospatial tasks, and show a slightly reduced rate of decline. In Huntington’s disease, higher CR is associated with better cognition in patients and in prodromal gene carriers over time. In Alzheimer’s disease, there is evidence of a different pattern. Higher CR is associated with better performance at baseline, but this is followed by a sharper rate of decline once symptoms emerge. 40 This suggests that CR may operate by delaying the onset of clinical symptoms rather than reducing the overall rate of decline.

The factors that contribute to preserved cognition in high CR individuals remain unclear, but could relate to overall network integrity, mediated by in part by preserved grey matter volume. In this case, the high CR individual may be better able to compensate for disease mediated neuronal injury and network disruption. The results of this study support previous longitudinal studies in ALS that those with normal cognition remain relatively stable over time, at least following diagnosis. 41–43 The utilisation of joint models to control for non-random drop-out, suggests that the lack of decline is not solely attributable to the drop-out of highly impaired patients.

Limitations
Our analysis of cognition was limited to 16 months follow-up; therefore, we have not characterised the rate of decline over the longer-term disease course. This study is also limited by the lack of a control group which would have given an indication of practice effects and the extent to which scores regress towards the mean. Future studies should compare the role of CR over a longer period, and relative to healthy controls and similar patient groups.

Disease progression was approximated using time since symptom onset to the point of neuropsychological assessment. This assumes a linear relationship between time and disease progression, which is not often the case. Furthermore, this study is limited by the lack of neuropathological and neuroimaging data. Further work will be required to characterise the relationship between CR and the underlying neuropathological, neuroimaging and neuroelectric changes associated with cognitive impairment in ALS. Specifically, studies may consider examining if CR moderates the relationship between DT-MRI (Diffusion Tensor Magnetic Resonance Imaging) abnormalities in the corpus callosum and frontotemporal tracts and neuropsychological outcomes. 41 Similarly, studies could explore if CR mediates the association between 18F-FDG-PET (Flourine-18 Fluorodeoxyglucose Positron Emission Tomography) measured hypometabolism in the frontal cortex and cognitive impairment. 42–44

Conclusion
Our findings show that higher CR is associated with better neuropsychological performance, particularly in domains associated with ALS, where the differential between high and low CR was maintained over time. However, given the limitations of the study, future research is required to explore the relationship between CR and the underlying neuroimaging, neuroelectric and neuropathological signatures of impairment in ALS.

Twitter Emmet Costello @EmmetCostello, James Rooney @jpkrooney, Roisin McMackin @RoisinTCDNeuro and Niall Pender @PenderNiall
Acknowledgements We wish to thank all those who partook in this research project, without whom this study would not be possible.
Contributors EC, OH and NP designed and conceptualised the study. EC, JR, MP-G, TB, ME, PB, MH and AV played a major role in the acquisition of data. EC and JR analysed and interpreted the data. EC drafted the manuscript for intellectual

Table 3  Cognitive reserve fixed effect for each neuropsychological test from joint model summary

<table>
<thead>
<tr>
<th>Outcome</th>
<th>β (SE)</th>
<th>95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECAS total</td>
<td>0.37 (0.003)</td>
<td>0.11 to 0.64</td>
<td>0.003</td>
</tr>
<tr>
<td>ECAS ALS specific</td>
<td>0.40 (0.002)</td>
<td>0.21 to 0.59</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ECAS ALS non-specific</td>
<td>0.26 (0.003)</td>
<td>0.06 to 0.44</td>
<td>0.01</td>
</tr>
<tr>
<td>Reading the mind in the eyes</td>
<td>0.66 (0.005)</td>
<td>0.26 to 1.04</td>
<td>0.002</td>
</tr>
<tr>
<td>Verbal fluency (unrestricted)</td>
<td>0.49 (0.007)</td>
<td>−0.15 to 1.16</td>
<td>0.13</td>
</tr>
<tr>
<td>Verbal fluency (restricted)</td>
<td>0.61 (0.02)</td>
<td>−0.73 to 1.99</td>
<td>0.39</td>
</tr>
<tr>
<td>CWIT inhibition</td>
<td>0.87 (0.008)</td>
<td>0.27 to 1.49</td>
<td>0.009</td>
</tr>
<tr>
<td>CWIT switching</td>
<td>0.63 (0.09)</td>
<td>0.17 to 1.07</td>
<td>0.008</td>
</tr>
<tr>
<td>Boston naming task</td>
<td>0.55 (0.005)</td>
<td>0.13 to 0.98</td>
<td>0.01</td>
</tr>
<tr>
<td>RAVLT total</td>
<td>0.29 (0.004)</td>
<td>−0.02 to 0.59</td>
<td>0.07</td>
</tr>
<tr>
<td>RAVLT delayed</td>
<td>0.27 (0.004)</td>
<td>−0.15 to 0.58</td>
<td>0.25</td>
</tr>
<tr>
<td>Logical memory immediate</td>
<td>0.38 (0.004)</td>
<td>0.02 to 0.72</td>
<td>0.04</td>
</tr>
<tr>
<td>Logical memory delayed</td>
<td>0.56 (0.005)</td>
<td>0.11 to 0.99</td>
<td>0.03</td>
</tr>
</tbody>
</table>

ALS, amyotrophic lateral sclerosis; CWIT, Colour-Word Interference Test; ECAS, Edinburgh cognitive and behavioural ALS screen; RAVLT, Rey Auditory Verbal Learning Test.
Cognition

Figure 1  High CR defined as having a CR Z score >1; medium CR defined as having a CR Z score between +1 and −1; low CR defined as having a CR Z score <−1. ALS, amyotrophic lateral sclerosis; CR, cognitive reserve; CWIT, Colour-Word Interference Test; ECAS, Edinburgh cognitive and behavioural ALS screen; LM, logical memory; RAVLT, Rey Auditory Verbal Learning Test.

content. EC, JR, MP-G, TB, ME, RM, SD, PB, MH, OH and NP revised the manuscript for intellectual content.

Funding  This research has received funding from Science Foundation Ireland (SFI), grant 16/ERC/3854, grant number 205532, the European Community’s Seventh Framework Programme (FP7/2007-2013) under the Health Cooperation programme and the project EUROMOTOR (no 259867), and the Charities Research Motor Neurone (no grant number) and Irish Motor Neurone Disease Association (no grant number). Peter Bede is supported by the Health Research Board (HRB EIA-2017-019), the EU Joint Programme–Neurodegenerative Disease Research (JPNH-2017-1), the Andrew Lydon scholarship (No grant number), and the Iris O’Brien Foundation (no grant number). JR is supported by the European Union Marie Skłodowska-Curie Action (no 846794).

Competing interests  NP serves as Associate Editor of the International Journal of Neuroscience and has received speaker honoraria from Novartis. OH has received speaking honoraria from Janssen Cilag, Biogen Idec, Sanofi Aventis, MerckSerono. She has been a member of advisory panels for Biogen Idec, Allergen, Ono Pharmaceuticals, Novartis, Cytokinetics and Sanofi Aventis. She serves as editor-in-chief of the journal Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

Patient consent for publication  Not required.

Ethics approval  Ethical approval was granted by Beaumont Hospital ethics committee (ID: REC Ref- 06/79 and REC Ref- 13/102).

Provenance and peer review  Not commissioned; externally peer reviewed.

Data availability statement  Anonymised data are available on reasonable request.

Supplemental material  This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and
responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMI does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omission arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID IDs
Emmet Costello http://orcid.org/0000-0001-8620-9531
James Rooney http://orcid.org/0000-0001-6346-0731
Marta Pinto-Grau http://orcid.org/0000-0003-0836-6093
Tom Burke http://orcid.org/0000-0002-6563-1597
Orla Hardiman http://orcid.org/0000-0003-2610-1291
Niall Pender http://orcid.org/0000-0002-4172-0704

REFERENCES